Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 5 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.

Contemporary combined hormonal contraceptives protect against ovarian cancer

07 Oct 2018

Contemporary combined hormonal contraceptives, such as desogestrel, gestodene and drospirenone, reduce the risk of ovarian cancer in women of reproductive age, a recent study has shown.

Researchers enrolled 1,879,227 women aged 15–49 years and who had no cancer, venous thrombosis or infertility treatments. Poisson regression analysis was performed to determine the risk of ovarian cancer among those who used any contemporary combined hormonal contraceptives.

Over the study duration of 20 years (21.4 million person-years), researchers documented 1,249 incident ovarian cancers in the study population, with the median age at diagnosis being 44.4 years.

Stratified analysis showed that in never users of any hormone contraceptives, 771 incident ovarian cancers developed over 8,150,250 person-years of follow-up. In comparison, 478 cases over 13,344,531 person-years were reported among ever users.

Moreover, the age-adjusted incidence rate of ovarian cancer was higher in never users vs ever users of any hormonal contraception (7.5 vs 4.3 per 100,000 person-years), resulting in a significant risk difference (adjusted relative risk [RR], 0.66; 95 percent CI, 0.58–0.76).

The protective effect of hormonal contraceptives against ovarian cancer was stronger for women who took combined oral (adjusted RR, 0.53; 0.45–0.64) than progestogen-only (adjusted RR, 0.72; 0.55–0.95) products.

Notably, the effect was diminished with time since last contraceptive use. The risk of ovarian cancer was comparable between never users and ever users by 10 years since last reported use of any hormonal contraception (adjusted RR, 0.80; 0.59–1.08).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 5 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.